( 01530.hk) | 4.65 | 1.45 | 1.45% (1.45%) | 上市时间2015-06-11股价17.28港币涨跌幅-1.65%成交金额2.27亿港币换手率0.52%市值438.58亿港币H股市值438.58亿港币总股本25.38亿H股本25.38亿每手股数500上市至今年化投资收益率6.80%港股通持仓占H股比例42.27% (185.49亿港币2026-07-22) 累计做空占H股比例7.37% (30.20亿港币2026-07-17) | |||
| 所属三级行业药品 (恒生) | 市盈率 | 27.47 | 市净率 | 2.47 | 股息率 | 1.38% (1.37%) | 恒生:医疗保健业药品及生物科技药品 |
| 所属指数指数纳入纳出 |
| ||||||
| 备注 (8): | 双击编辑备注 |
三生制药(01530) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 張丹 | Independent Non Executive Director | 2022-12-30 | -- | |
| 2 | 黃祖耀 | Independent Non Executive Director - A/F | 2022-01-21 | -- | |
| 3 | 楊凱蒂 | Independent Non Executive Director | 2021-06-29 | -- | |
| 4 | 唐柯 | Non Executive Director | 2020-02-10 | 2022-12-30 | |
| 5 | 黃立恩 | Independent Non Executive Director | 2019-10-08 | 2022-01-21 | |
| 6 | 黃斌 | Non Executive Director | 2019-06-20 | -- | |
| 7 | 王瑞 | Independent Non Executive Director | 2019-06-20 | 2019-10-08 | |
| 8 | 王大松 | Non Executive Director | 2017-06-30 | 2019-10-08 | |
| 9 | 濮天若 | Independent Non Executive Director - A/F | 2015-05-23 | -- | |
| 10 | PARKINSON DAVID ROSS | Independent Non Executive Director | 2015-05-23 | 2021-06-29 | |
| 11 | 馬駿 | Independent Non Executive Director | 2015-05-23 | 2019-06-20 | |
| 12 | 劉東 | Non Executive Director | 2014-11-27 | 2020-02-10 | |
| 13 | 黃斌 | Executive Director | 2014-11-27 | 2019-06-20 | |
| 14 | 呂東 | Non Executive Director | 2014-11-27 | 2017-06-30 | |
| 15 | 譚擘 | Executive Director | 2013-05-29 | 2019-12-02 | |
| 16 | 蘇冬梅 | Executive Director | 2012-06-11 | -- | |
| 17 | 婁競 | Executive Director | Chairman, CEO | 2006-09-05 | -- |